Procore signs multi-year strategic collaboration agreement with AWS
scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company with a market capitalization of $260.1 million and impressive revenue growth of 108% over the last twelve months, announced Monday that it has entered into an amendment to its supply agreement with West Pharmaceutical Services, Inc. The amendment, effective August 20, 2025, modifies the original agreement dated August 15, 2020, under which scPharmaceuticals agreed to purchase the SmartDose drug delivery system developed by West. According to InvestingPro data, the company maintains a healthy current ratio of 3.85, indicating strong ability to meet its supply commitments.
According to a statement in the SEC filing, the amended agreement extends the term of the supply arrangement through December 31, 2027. The agreement will not automatically extend or renew beyond that date. The amendment also specifies that if either party elects to terminate the agreement, scPharmaceuticals will be responsible for payment to West for any costs incurred and purchase orders accepted through the date of termination.
The company filed the amendment as an exhibit to the Form 8-K submitted to the Securities and Exchange Commission. No additional financial terms or details regarding the volume of purchases were disclosed in the filing.
This report is based on a statement from a press release included in the SEC filing.
In other recent news, SC Pharmaceuticals reported its Q2 2025 earnings, showcasing a mixed financial performance. The company achieved net revenue of $16 million, which exceeded forecasts and represented a significant 99% increase compared to the previous year. Despite this positive revenue growth, the earnings per share (EPS) did not meet expectations, coming in at -$0.34 instead of the anticipated -$0.29. These recent developments highlight the company’s ability to grow revenue while facing challenges in achieving projected earnings. The market’s reaction to the EPS miss was notably negative. However, the revenue growth indicates strong underlying business momentum. Investors will be keenly observing how SC Pharmaceuticals addresses its earnings performance in the coming quarters.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.